Therapeutic: symptomatic infection to hospitalisation 100 -Patient risk: — low mixed 80 high Trial Efficacy [%] 60 -Chew (bamlanivimab, 0.7g) Chew (bamlanivimab, 7g) Dougan (bamlanivimab + etesevimab, 2.1g) Eom (regdanvimab, 40mg/kg) 40 -Eom (regdanvimab, 80mg/kg) Gupta (sotrovimab, 0.5g) Libster (CP >,200) Libster (CP 1,000-3,200) 20 -Millat-Martinez Montgomery (cilgavimab + tixagevimab, 0.6g) Sullivan 10 0.1 100 1000 Dose [fold convalescent]